DexCom, Inc. $DXCM Shares Sold by Peregrine Capital Management LLC

Peregrine Capital Management LLC lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 2.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 530,928 shares of the medical device company’s stock after selling 10,948 shares during the period. DexCom makes up approximately 1.1% of Peregrine Capital Management LLC’s portfolio, making the stock its 20th biggest holding. Peregrine Capital Management LLC owned approximately 0.14% of DexCom worth $35,726,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the stock. GAMMA Investing LLC raised its position in shares of DexCom by 2.5% in the 3rd quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company’s stock worth $474,000 after buying an additional 169 shares during the period. Inspire Investing LLC grew its position in DexCom by 6.1% during the third quarter. Inspire Investing LLC now owns 3,139 shares of the medical device company’s stock valued at $211,000 after acquiring an additional 180 shares during the period. Meiji Yasuda Asset Management Co Ltd. increased its stake in DexCom by 3.2% during the first quarter. Meiji Yasuda Asset Management Co Ltd. now owns 6,019 shares of the medical device company’s stock worth $411,000 after acquiring an additional 187 shares during the last quarter. Integrated Wealth Concepts LLC raised its holdings in shares of DexCom by 6.3% in the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after purchasing an additional 196 shares during the period. Finally, STF Management LP lifted its stake in shares of DexCom by 5.5% in the 2nd quarter. STF Management LP now owns 4,041 shares of the medical device company’s stock valued at $353,000 after purchasing an additional 211 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently issued reports on DXCM. Cowen reissued a “buy” rating on shares of DexCom in a research report on Friday, October 24th. Canaccord Genuity Group set a $99.00 price objective on shares of DexCom and gave the stock a “buy” rating in a research report on Friday, October 31st. Piper Sandler set a $75.00 target price on shares of DexCom and gave the company a “buy” rating in a report on Friday, October 31st. UBS Group lowered their price target on DexCom from $106.00 to $95.00 and set a “buy” rating for the company in a report on Monday, November 3rd. Finally, Sanford C. Bernstein restated an “outperform” rating on shares of DexCom in a research note on Friday. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average target price of $86.61.

DexCom Stock Performance

DexCom stock opened at $68.43 on Friday. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $93.25. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.56 and a quick ratio of 1.38. The company has a market capitalization of $26.69 billion, a price-to-earnings ratio of 38.02, a price-to-earnings-growth ratio of 1.26 and a beta of 1.48. The firm’s fifty day moving average price is $63.74 and its 200 day moving average price is $72.29.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.04. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The company had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. During the same period last year, the firm earned $0.45 earnings per share. The company’s revenue was up 21.6% on a year-over-year basis. On average, research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In other DexCom news, Director Richard Alexander Collins sold 2,906 shares of DexCom stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $59.05, for a total transaction of $171,599.30. Following the sale, the director directly owned 35,088 shares in the company, valued at $2,071,946.40. The trade was a 7.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jacob Steven Leach bought 18,200 shares of DexCom stock in a transaction dated Monday, November 10th. The shares were acquired at an average price of $55.04 per share, with a total value of $1,001,728.00. Following the completion of the purchase, the chief operating officer owned 331,697 shares in the company, valued at approximately $18,256,602.88. The trade was a 5.81% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders sold a total of 7,866 shares of company stock worth $448,177 in the last 90 days. 0.32% of the stock is owned by corporate insiders.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.